GB1583802A - Use of moxnidazole for combating diseases in the veterinary field - Google Patents
Use of moxnidazole for combating diseases in the veterinary field Download PDFInfo
- Publication number
- GB1583802A GB1583802A GB2655377A GB2655377A GB1583802A GB 1583802 A GB1583802 A GB 1583802A GB 2655377 A GB2655377 A GB 2655377A GB 2655377 A GB2655377 A GB 2655377A GB 1583802 A GB1583802 A GB 1583802A
- Authority
- GB
- United Kingdom
- Prior art keywords
- moxnidazole
- treatment
- preparation
- fowl
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- RILWUTQZRXWBOB-GIDUJCDVSA-N 3-[(e)-(1-methyl-5-nitroimidazol-2-yl)methylideneamino]-5-(morpholin-4-ylmethyl)-1,3-oxazolidin-2-one Chemical compound C1=C([N+]([O-])=O)N(C)C(\C=N\N2C(OC(CN3CCOCC3)C2)=O)=N1 RILWUTQZRXWBOB-GIDUJCDVSA-N 0.000 title claims description 71
- 229950002396 moxnidazole Drugs 0.000 title claims description 71
- 201000010099 disease Diseases 0.000 title description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 4
- 238000011282 treatment Methods 0.000 claims description 42
- 241001465754 Metazoa Species 0.000 claims description 32
- 241000272201 Columbiformes Species 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- 241000282898 Sus scrofa Species 0.000 claims description 19
- 235000020188 drinking water Nutrition 0.000 claims description 18
- 239000003651 drinking water Substances 0.000 claims description 18
- 208000010362 Protozoan Infections Diseases 0.000 claims description 17
- 241000282887 Suidae Species 0.000 claims description 17
- 208000005448 Trichomonas Infections Diseases 0.000 claims description 14
- 206010044620 Trichomoniasis Diseases 0.000 claims description 14
- 208000001848 dysentery Diseases 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 9
- 241000272496 Galliformes Species 0.000 claims description 8
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 3
- 235000019764 Soybean Meal Nutrition 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 229910052918 calcium silicate Inorganic materials 0.000 claims description 3
- 239000000378 calcium silicate Substances 0.000 claims description 3
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 235000012054 meals Nutrition 0.000 claims description 3
- 239000004455 soybean meal Substances 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 2
- XOXHILFPRYWFOD-UHFFFAOYSA-N sulfachloropyridazine Chemical group C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=C(Cl)N=N1 XOXHILFPRYWFOD-UHFFFAOYSA-N 0.000 claims description 2
- 239000004552 water soluble powder Substances 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 241000286209 Phasianidae Species 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 241000271566 Aves Species 0.000 description 16
- 238000012360 testing method Methods 0.000 description 12
- 244000144992 flock Species 0.000 description 10
- 206010012735 Diarrhoea Diseases 0.000 description 9
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 9
- NTAFJUSDNOSFFY-UHFFFAOYSA-N Ipronidazole Chemical compound CC(C)C1=NC=C([N+]([O-])=O)N1C NTAFJUSDNOSFFY-UHFFFAOYSA-N 0.000 description 6
- 241000589886 Treponema Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 208000003495 Coccidiosis Diseases 0.000 description 5
- 206010023076 Isosporiasis Diseases 0.000 description 5
- 229950000107 ipronidazole Drugs 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241000224483 Coccidia Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 241000252983 Caecum Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001502500 Trichomonadida Species 0.000 description 2
- 241000224527 Trichomonas vaginalis Species 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- -1 compound 3-(1-methyl-5-nitro-2- imidazolyl - methyleneamino) - 5 - morpholinomethyl - 2 - oxazolidinone - hydrochloride Chemical class 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003746 feather Anatomy 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 241000589893 Brachyspira hyodysenteriae Species 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000499566 Eimeria brunetti Species 0.000 description 1
- 241000223934 Eimeria maxima Species 0.000 description 1
- 241000499563 Eimeria necatrix Species 0.000 description 1
- 241000223932 Eimeria tenella Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001142635 Lema Species 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 241000589973 Spirochaeta Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003555 cloaca Anatomy 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- IBXPYPUJPLLOIN-UHFFFAOYSA-N dimetridazole Chemical compound CC1=NC=C(N(=O)=O)N1C IBXPYPUJPLLOIN-UHFFFAOYSA-N 0.000 description 1
- 229960000946 dimetridazole Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000004957 nitroimidazoles Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000003108 parasitologic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 239000012658 prophylactic medication Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- PQFRTXSWDXZRRS-UHFFFAOYSA-N ronidazole Chemical compound CN1C(COC(N)=O)=NC=C1[N+]([O-])=O PQFRTXSWDXZRRS-UHFFFAOYSA-N 0.000 description 1
- 229960001505 ronidazole Drugs 0.000 description 1
- 208000012331 ruffled feather Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19762629237 DE2629237A1 (de) | 1976-06-26 | 1976-06-26 | Mittel zur bekaempfung von erkrankungen im veterinaerbereich |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1583802A true GB1583802A (en) | 1981-02-04 |
Family
ID=5981782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2655377A Expired GB1583802A (en) | 1976-06-26 | 1977-06-24 | Use of moxnidazole for combating diseases in the veterinary field |
Country Status (7)
| Country | Link |
|---|---|
| BE (1) | BE856097A (enExample) |
| DE (1) | DE2629237A1 (enExample) |
| DK (1) | DK259877A (enExample) |
| GB (1) | GB1583802A (enExample) |
| IT (1) | IT1125787B (enExample) |
| LU (1) | LU77615A1 (enExample) |
| NL (1) | NL7706595A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1810815B (zh) * | 2006-03-08 | 2011-03-16 | 陕西合成药业有限公司 | 用于治疗的硝基咪唑衍生物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1920150C2 (de) | 1969-04-17 | 1983-01-13 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | 3-(l-Methyl-5-nitro-2-imidazolyl-methylenamino)-2-oxazolidone |
| US3737546A (en) | 1972-09-15 | 1973-06-05 | Hoffmann La Roche | Use of ipronidazole in combatting swine dysentery |
| YU35244B (en) | 1973-02-20 | 1980-10-31 | Galenika Beograd Zemun | Process for the preparation and isolation of 4-and 5-nitroimidazoles |
-
1976
- 1976-06-26 DE DE19762629237 patent/DE2629237A1/de not_active Ceased
-
1977
- 1977-06-13 DK DK259877A patent/DK259877A/da not_active Application Discontinuation
- 1977-06-15 NL NL7706595A patent/NL7706595A/xx not_active Application Discontinuation
- 1977-06-24 BE BE178771A patent/BE856097A/xx unknown
- 1977-06-24 IT IT2503777A patent/IT1125787B/it active
- 1977-06-24 GB GB2655377A patent/GB1583802A/en not_active Expired
- 1977-06-24 LU LU77615A patent/LU77615A1/xx unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1810815B (zh) * | 2006-03-08 | 2011-03-16 | 陕西合成药业有限公司 | 用于治疗的硝基咪唑衍生物 |
Also Published As
| Publication number | Publication date |
|---|---|
| BE856097A (fr) | 1977-12-27 |
| DK259877A (da) | 1977-12-27 |
| IT1125787B (it) | 1986-05-14 |
| LU77615A1 (enExample) | 1977-10-03 |
| NL7706595A (nl) | 1977-12-28 |
| DE2629237A1 (de) | 1978-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2707076C2 (ru) | Комбинация, композиция и способ введения комбинации или композиции животным | |
| JPH08231410A (ja) | コクシジウム症軽減剤及びそれを含有する飼料 | |
| Hartley et al. | Muscular dystrophy in New Zealand livestock | |
| JPH0347132A (ja) | 原虫性疾患の予防治療剤 | |
| US5618847A (en) | Medicinal feed for the systemic treatment of ectoparasitic and ectobacterial diseases of fish | |
| US5063219A (en) | Anticoccidial composition | |
| JPS63287722A (ja) | コクシジウム症の予防および処置のための組成物 | |
| EP0158075A1 (de) | Immunstimulierende Mittel | |
| US5215993A (en) | Anticoccidial compositions | |
| US4861758A (en) | Coccidiocidal compositions | |
| US4824847A (en) | Coccidiocidal compositions | |
| JPH03500243A (ja) | ２‐デオキシ‐ｄ‐ヘキソースの経口投与による産肉性動物の飼料要求率の改良方法 | |
| US2893914A (en) | Thiadicarbocyanine anthelmintic compositions and methods of using them | |
| Snieszko et al. | The effect of some sulfonamides on the growth of brook trout, brown trout, and rainbow trout | |
| JPS6043097B2 (ja) | 飼料利用効率改善剤 | |
| GB1583802A (en) | Use of moxnidazole for combating diseases in the veterinary field | |
| DE2759108A1 (de) | Verwendung von alpha -mercapto-beta- aryl-acrylsaeuren bei der steigerung des zinkgehaltes im serum und im gewebe | |
| EP0086774A1 (en) | Treatment of coccidial infections with amidinourea or amidinothiourea derivatives | |
| Bortree et al. | Ascorbic Acid Stimulation in the Blood Plasma of Dairy Cattle Produced by the Ingestion of Chlorobutanol | |
| JP2002505257A (ja) | ベンゾイルフェニル尿素を含む殺菌剤組成物 | |
| US2797182A (en) | Cadmium anthranilate containing anthelmintics | |
| US3773943A (en) | Alpha,alpha,alpha-trifluoro-6-substituted-5-nitro-m-toluic acid,5'-nitrofurylidene hydrazide compounds as growth promotants | |
| US4205081A (en) | Composition and method for preventing or treating swine dysentery | |
| JPH07173055A (ja) | 抗コクシジウム組成物 | |
| RU2813776C1 (ru) | Способ лечения сальмонеллеза у молодняка крупного рогатого скота |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CSNS | Application of which complete specification have been accepted and published, but patent is not sealed |